← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT07112196

Visugromab in Cachexia International Trial

Trial Parameters

Condition Cancer-associated Cachexia
Sponsor CatalYm GmbH
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 518
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2026-01
Completion 2029-12
Interventions
Visugromab (CTL-002)PlaceboVisugromab (CTL-002)

Brief Summary

A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.

Eligibility Criteria

Inclusion Criteria: * Weight loss * Advanced cancer Exclusion Criteria: * Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product

Related Trials